Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

医学 伊马替尼 中止 内科学 甲磺酸伊马替尼 中期分析 前瞻性队列研究 髓系白血病 外科 临床试验
作者
François‐Xavier Mahon,Delphine Réa,Joëlle Guilhot,François Guilhot,Françoise Huguet,Franck E. Nicolini,Laurence Legros,Aude Charbonnier,Agnès Guerci,Bruno Varet,Gabriel Étienne,Josy Reiffers,Philippe Rousselot
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:11 (11): 1029-1035 被引量:1521
标识
DOI:10.1016/s1470-2045(10)70233-3
摘要

Background Imatinib treatment significantly improves survival in patients with chronic myeloid leukaemia (CML), but little is known about whether treatment can safely be discontinued in the long term. We aimed to assess whether imatinib can be discontinued without occurrence of molecular relapse in patients in complete molecular remission (CMR) while on imatinib. Methods In our prospective, multicentre, non-randomised Stop Imatinib (STIM) study, imatinib treatment (of >2 years duration) was discontinued in patients with CML who were aged 18 years and older and in CMR (>5-log reduction in BCR–ABL and ABL levels and undetectable transcripts on quantitative RT-PCR). Patients who had undergone immunomodulatory treatment (apart from interferon α), treatment for other malignancies, or allogeneic haemopoietic stem-cell transplantation were not included. Patients were enrolled at 19 participating institutions in France. In this interim analysis, rate of relapse was assessed by use of RT-PCR for patients with at least 12 months of follow-up. Imatinib was reintroduced in patients who had molecular relapse. This study is registered with ClinicalTrials.gov, number NCT00478985. Findings 100 patients were enrolled between July 9, 2007, and Dec 17, 2009. Median follow-up was 17 months (range 1–30), and 69 patients had at least 12 months follow-up (median 24 months, range 13–30). 42 (61%) of these 69 patients relapsed (40 before 6 months, one patient at month 7, and one at month 19). At 12 months, the probability of persistent CMR for these 69 patients was 41% (95% CI 29–52). All patients who relapsed responded to reintroduction of imatinib: 16 of the 42 patients who relapsed showed decreases in their BCR–ABL levels, and 26 achieved CMR that was sustained after imatinib rechallenge. Interpretation Imatinib can be safely discontinued in patients with a CMR of at least 2 years duration. Imatinib discontinuation in this setting yields promising results for molecular relapse-free survival, raising the possibility that, at least in some patients, CML might be cured with tyrosine kinase inhibitors. Funding French Ministry of Health (Programme Hospitalier de Recherche 2006 grants), Institut National du Cancer (INCA).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
zyz完成签到,获得积分10
刚刚
大个的应助被as采纳,获得10
1秒前
zz完成签到,获得积分20
1秒前
bobby完成签到,获得积分10
1秒前
baihehuakai发布了新的文献求助10
2秒前
L。发布了新的文献求助10
2秒前
英姑的应助被科研小天才采纳,获得10
2秒前
Moon发布了新的文献求助10
3秒前
jjjwwww的应助被wzh采纳,获得10
3秒前
3秒前
JamesPei的应助被叽里呱啦采纳,获得10
3秒前
wgf关注了科研通微信公众号
4秒前
wanci的应助被留不住的神采纳,获得10
4秒前
上官小怡发布了新的文献求助10
4秒前
wjy发布了新的文献求助10
5秒前
赘婿的应助被礼者采纳,获得10
5秒前
嘻嘻哈哈发布了新的文献求助110
5秒前
5秒前
斯巴达发布了新的文献求助10
6秒前
My_magnum_opus给肌因科学的求助进行了留言
6秒前
6秒前
无极微光的应助被发总采纳,获得20
6秒前
充电宝的应助被善良的秋蝶采纳,获得10
7秒前
JamesPei的应助被健康的小蝴蝶采纳,获得10
8秒前
罗杰发布了新的文献求助10
8秒前
gxy完成签到,获得积分10
8秒前
liu发布了新的文献求助10
8秒前
8秒前
9秒前
罗杰发布了新的文献求助10
9秒前
9秒前
王泽业发布了新的文献求助10
9秒前
罗杰发布了新的文献求助10
10秒前
罗杰发布了新的文献求助10
10秒前
10秒前
dyk发布了新的文献求助10
10秒前
10秒前
罗杰发布了新的文献求助10
10秒前
wenyu_Tan发布了新的文献求助10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Monte Cassino in the Middle Ages Volume I 310
JUSTIFICATION OF SMALL-SCALE MODELS: AN INDUSTRY PERSPECTIVE 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8157019
求助须知:如何正确求助?哪些是违规求助? 9553131
关于积分的说明 21713003
捐赠科研通 7746165
什么是DOI,文献DOI怎么找? 3426705
关于科研通互助平台的介绍 2551467
邀请新用户注册赠送积分活动 2470603